Arcus Biosciences Inc (NYSE:RCUS) price on Friday, June 13, fall -1.18% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $9.24.
A look at the stock’s price movement, the close in the last trading session was $9.35. Turning to its 52-week performance, $18.98 and $6.50 were the 52-week high and 52-week low respectively. Overall, RCUS moved 8.20% over the past month.
Arcus Biosciences Inc’s market cap currently stands at around $978.38 million, with investors looking forward to this quarter’s earnings report slated for in July.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend RCUS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RCUS’s current price about -0.18% and 7.83% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.95, while 7-day volatility ratio is 5.77% and 4.01% in the 30-day chart. Further, Arcus Biosciences Inc (RCUS) has a beta value of 0.84, and an average true range (ATR) of 0.63. Analysts have given the company’s stock an average 52-week price target of $26, forecast between a low of $26 and high of $26. Looking at the price targets, the low is -181.39% off current price level while to achieve the yearly target high, price needs to move -181.39%. Nonetheless, investors will most likely welcome a -181.39% jump to $26 which is the analysts’ median price.
If we refocus on Arcus Biosciences Inc (NYSE:RCUS), historical trading data shows that trading volumes averaged 1.19 million over the past 3 months. The company’s latest data on shares outstanding shows there are 105.90 million shares.
The 39.66% of Arcus Biosciences Inc’s shares are in the hands of company insiders while institutional holders own 62.43% of the company’s shares. Current price change has pushed the stock -37.94% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RCUS stock continues to rise going into the next quarter.
